Key takeaways:
Injectable weight-loss medications like glucagon-like peptide-1 (GLP-1) receptor agonists can cost more than $1,000 a month without insurance.
Medicaid prescription coverage varies by state; those that cover weight-loss medications often require prior authorizations and have other coverage restrictions.
People with Medicaid can’t use manufacturer copay cards, but they may be able to use GoodRx coupons or manufacturer cash-pay programs if they pay outside of their Medicaid coverage.
Weight-loss medications have become increasingly popular as newer options have shown substantial benefits for weight management. But these long-term medications can cost over $1,000 per month without insurance. And this greatly affects access and adherence, according to GoodRx Research.
People with commercial insurance may have decent coverage or be eligible for manufacturer savings programs, like copay cards. And people with Medicare now have lower-cost access to certain weight-loss medications through the Medicare Bridge Program. But what about patients with Medicaid?
Does Medicaid cover weight-loss medications?
Here’s the short answer: It depends on the medication and the state. Coverage of glucagon-like peptide-1 (GLP-1) receptor agonists and other weight-loss medications remains optional for states, so programs vary widely.
Medicaid is a joint federal and state health insurance program for eligible low-income individuals and families in the U.S. Federal law requires states to cover certain benefits, while others are optional. Prescription medication coverage is technically optional, but all state Medicaid programs currently provide it.
The government's BALANCE program (Better Approaches to Lifestyle and Nutrition for Comprehensive hEalth) was designed to expand both Medicare and Medicaid coverage of GLP-1s. The Medicare component isn’t moving forward for 2027, but participating states began implementing the Medicaid portion on a rolling basis on May 1, 2026. The deadline for state Medicaid agencies to apply was July 31, 2026. The program’s long-term future remains uncertain.
So, as of mid-2026, some state Medicaid programs cover the cost of GLP-1s for weight loss, and some don’t. And those that do cover GLP-1s require prior authorization or step therapy first. They’re also likely to limit coverage to a preferred medication. Nonpreferred medications usually require prior authorization and cost more out of pocket.
It's also important to note that formularies can change at any time, meaning medications can be dropped and added throughout the year.
Which medications are covered?
Here’s a breakdown of coverage by medication.
Wegovy
Wegovy is the most commonly covered GLP-1 medication among states with Medicaid coverage for weight-loss medications. As above, it often requires prior authorization.
Without any coverage, the retail price of Wegovy is over $1,349 a month, but the retail price can vary depending on the pharmacy and location.
Patients can use NovoCare’s tool to see if Medicaid coverage is available.
Zepbound
Zepbound’s list price ranges from about $500 to $1,086 for a 28-day supply without insurance, depending on the dose.
Zepbound’s coverage and savings website can help you determine which Medicaid plans have added the medication to their formulary.
Foundayo
Foundayo is a small molecule (non-peptide), oral medication that was FDA approved for chronic weight management in April 2026. The list price for Foundayo is $649 for 30 tablets, a month's supply.
Foundayo is included in the BALANCE program, so as long as that program moves forward, patients will be able to access this medication.
Others
Patients may be more likely to ask for the newer weight-loss medications, but of course, they’re not the only options for chronic weight management. Consider these other medications, which Medicaid may cover in your state, including:
Qsymia (phentermine / topiramate)
Xenical (orlistat)
Contrave (naltrexone / bupropion)
Saxenda (liraglutide)
Medicaid may also cover other Type 2 diabetes medications that cause weight loss as a side effect, such as:
Keep in mind, there may still be certain eligibility criteria or prior authorization requirements for these.
Other ways to save
Patients with Medicaid plans that don’t cover their desired weight-loss medication can consider these cash-pay savings.
GoodRx
People with Medicaid and other government-run insurance plans are usually excluded from prescription savings programs. But they may be able to use GoodRx discounts on certain weight-loss medications if they choose to pay outside of their Medicaid coverage. A GoodRx discount can’t be combined with Medicaid coverage for the same prescription, and the purchase can’t be submitted to Medicaid for reimbursement.
Those who are new to using GoodRx for savings on weight-loss medications are eligible for the following:
Wegovy: The first 2 fills are $199 per month for the pen, and $149 per month for the pill (only available for certain doses). For future fills and for certain Wegovy doses, patients pay $349 or $399 per month for the pen and $199 per month for the pill.
Zepbound: Zepbound KwikPen and vials start at $299 per month.
Foundayo: Pricing starts at $149 per month. After that, most ongoing fills are $299 or $349 per month, depending on the dose.
Manufacturer self-pay programs vs. copay cards
Some manufacturers offer discounted cash prices that don’t depend on insurance coverage. Patients who use these programs pay for the medication themselves rather than billing Medicaid. Examples of cash-pay programs include:
Wegovy pills and pens can be delivered through NovoCare Pharmacy for $149-$199 per month.
Zepbound single-dose vials and KwikPens are available through LillyDirect for $299 (2.5 mg), $399 (5 mg), and $449 (7.5 mg, 10 mg, 12.5 mg, and 15 mg) per month.
Foundayo is also available through LillyDirect starting at $149 (0.8 mg), $199 (2.5 mg), and $249 (5.5 mg, 9 mg, 14.5 mg, and 17.2 mg) per month.
Manufacturer copay cards work differently. They’re generally limited to people with commercial insurance, so people with Medicaid usually do not qualify.
The bottom line
Medicaid coverage of weight-loss medications like glucagon-like peptide-1 (GLP-1) receptor agonists varies by state. Some programs cover FDA-approved medications for weight management, such as Wegovy (semaglutide) and Saxenda (liraglutide). They often have restrictions such as prior authorization, step therapy, or eligibility requirements.
If a patient’s Medicaid plan doesn’t cover their medication, they may still have lower-cost options. These can include manufacturer self-pay programs and GoodRx coupons, which can be used outside of Medicaid coverage.
Why trust our experts?
References
American Academy of Procedural Medicine. (2026). Does Medicaid cover weight-loss medication? A state-by-state guide.
Centers for Medicare & Medicaid Services. (n.d.). BALANCE (Better Approaches to Lifestyle and Nutrition for Comprehensive hEalth) Model.
Centers for Medicare & Medicaid Services. (n.d.). Prescription drugs.
Eli Lilly and Company. (n.d.). How much should I expect to pay for Foundayo (orforglipron)?
Eli Lilly and Company. (n.d.). How much should I expect to pay for Zepbound (tirzepatide)?
Eli Lilly and Company. (2023). Lilly's tirzepatide shows additional 21.1% weight loss after 12 weeks of intensive lifestyle intervention, for a total mean weight loss of 26.6% from study entry over 84 weeks.
Eli Lilly and Company. (n.d.). Zepbound: Explore savings options.
Forrester, C. (2020). Benefits of prior authorizations. Journal of Managed Care & Specialty Pharmacy.
Freed, M., et al. (2026). What to know about the BALANCE Model for GLP-1s in Medicare and Medicaid and the Medicare GLP-1 Bridge. KFF.
Kansteiner, F. (2025). Novo's Wegovy picks up 3rd indication with key FDA approval in the liver disease MASH. Fierce Pharma.
Lilly Direct. (n.d.). Foundayo (orforglipron): Now available. Eli Lilly and Company.
Lilly Direct. (n.d.). Zepbound (tirzepatide). Eli Lilly and Company.
NovoCare. (n.d.). Wegovy.
U.S. Food and Drug Administration. (2023). FDA approves new medication for chronic weight management.
U.S. Food and Drug Administration. (2025). FDA approves treatment for serious liver disease known as ‘MASH’.
Wilding, J. P. H., et al. (2021). Once weekly semaglutide in adults with overweight or obesity. The New England Journal of Medicine.
Williams, E. (2026). Medicaid coverage of and spending on GLP-1s. KFF.
Zepbound. (n.d.). Savings card, cost, and coverage support. Eli Lilly and Company.
